Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTR 107

Next Previous
X
Search
Drug Profile

CTR 107

Alternative Names: CTR-107; Noregen™ - Caeregen Therapeutics

Latest Information Update: 25 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Caeregen Therapeutics
  • Class Cell therapies; Eye disorder therapies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial exudative vitreoretinopathy
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Familial exudative vitreoretinopathy; Retinal vein occlusion

Most Recent Events

  • 24 Jul 2023 Preclinical trials in Retinal vein occlusion in USA (unspecified route), prior to July 2023 (Caeregen Therapeutics pipeline, July 2023)
  • 24 Jul 2023 Caeregen Therapeutics plans a first phase Ia/b trial for Retinal vein occlusion (Caeregen Therapeutics pipeline, July 2023)
  • 17 Jul 2023 Caeregen Therapeutics receives a SBIR grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR 107 for the treatment of retinal-related vision loss due to a wide range of inherited and age-related diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top